Celgene, AbbVie extract pricing gains as Gilead, J&J meds net less by Eric Sagonowsky Tuesday, April 3, 2018 Higher net prices for Humira and Revlimid fueled growth in the fourth quarter for AbbVie and Celgene, respectively, a report found.
Celgene COO Smith exits suddenly in wake of MS miss by Arlene Weintraub Tuesday, April 3, 2018 The departure of Celgene COO Scott Smith wasn't entirely surprising, given recent setbacks, including a delayed FDA decision on the company's MS candidate ozanimod.
Relax, Celgene investors. The situation isn't all that bad: analyst by Carly Helfand Thursday, March 29, 2018 Celgene’s stock has taken a beating thanks to a string of bad news. But the situation isn’t as dire as its share price suggests, one analyst insists.
On the heels of its Juno buy, Celgene posts double-digit growth by Eric Sagonowsky Thursday, January 25, 2018 Despite struggles in 2017, Celgene turned in 16% annual sales growth, buoyed by key drugs Revlimid, Pomalyst and Otezla.
Celgene expects growth as it puts setbacks behind it by Eric Sagonowsky Monday, January 8, 2018 SAN FRANCISCO—Looking to recover from a tough year, Celgene rolled out its 2018 guidance at the J.P. Morgan Healthcare conference in San Francisco.
Celgene's latest Revlimid fail raises bigger questions: analyst by Tracy Staton Friday, December 22, 2017 On a quest to make Revlimid a go-to lymphoma med, Celgene pitted a Revlimid-Rituxan combo against standard of care. It failed.
Celgene wipes $1B to $2B off its 2020 guidance by Eric Sagonowsky Thursday, October 26, 2017 Celgene on Thursday reported third-quarter financial results that further spooked investors.
Celgene takes aggressive price hikes on Revlimid, Pomalyst by Eric Sagonowsky Tuesday, October 24, 2017 Celgene hiked the list prices of key cancer meds Revlimid and Pomalyst by 9% this month.
Big Pharma offers blockbuster discounts to win China coverage by Angus Liu Wednesday, July 19, 2017 After an average 44% price cuts, Chinese government will add some blockbuster foreign meds like Celgene's Revlimid to its national insurance scheme.
FDA sidelines Keytruda myeloma studies after trial deaths by Carly Helfand Thursday, July 6, 2017 The FDA slapped a clinical hold on two Keytruda trials, dashing Merck's hopes of combining the IO star with one of Celgene's big-selling myeloma meds.
